News
Published Research in Nature Communications: PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity
Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional…
Partner News: UConn Health Opens New Cancer Trial with PVSRIPO
From the office of UConn Health: High-Profile Brain Tumor Trial Chooses UConn Health An immunotherapy…
Press Release: FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced…
Press Release: Istari Announces 1st Patient in LUMINOS-101 Trial of PVSRIPO with Pembrolizumab for rGBM
Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO…
Partner News: UH Seidman Cancer Center Opens New Trial with PVSRIPO
From the office of University Hospitals Seidman Cancer Center: UH Seidman Cancer Center Opens New…
Press Release: Istari to Open LUMINOS-102 Trial in Treatment-Refractory Melanoma
Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without…
Press Release: Istari Oncology Presents Data from Phase 1 Melanoma Study
For the full poster on the Phase 1 trial click the button below.
Published Research in Nature Communications: Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity
Journal authors for the below study: Mubeen M. Mosaheb, Elena Y. Dobrikova, Michael C. Brown,…
Published Research in Science Advances: CReP mediates selective translation initiation at the endoplasmic reticulum
Journal authors for the below study: Jonathan P. Kastan, Elena Y. Dobrikova, Jeffrey D. Bryant,…
Announcing the new Istari Oncology website
Welcome to our new website; we invite you to look around. Please contact us if…